» Articles » PMID: 29421286

Application of Computational Methods for Anticancer Drug Discovery, Design, and Optimization

Overview
Specialty Pediatrics
Date 2018 Feb 9
PMID 29421286
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

Developing a novel drug is a complex, risky, expensive and time-consuming venture. It is estimated that the conventional drug discovery process ending with a new medicine ready for the market can take up to 15 years and more than a billion USD. Fortunately, this scenario has recently changed with the arrival of new approaches. Many novel technologies and methodologies have been developed to increase the efficiency of the drug discovery process, and computational methodologies have become a crucial component of many drug discovery programs. From hit identification to lead optimization, techniques such as ligand- or structure-based virtual screening are widely used in many discovery efforts. It is the case for designing potential anticancer drugs and drug candidates, where these computational approaches have had a major impact over the years and have provided fruitful insights into the field of cancer. In this paper, we review the concept of rational design presenting some of the most representative examples of molecules identified by means of it. Key principles are illustrated through case studies including specifically successful achievements in the field of anticancer drug design to demonstrate that research advances, with the aid of in silico drug design, have the potential to create novel anticancer drugs.

Citing Articles

Prediction of angiogenesis suppression by myricetin from via inhibiting VEGFR2 signaling pathway using computer-aided analysis.

Bhuiyan M, Ahmed K, Reza M, Hossain H, Siam S, Nayan S Heliyon. 2025; 11(2):e41749.

PMID: 39897831 PMC: 11786634. DOI: 10.1016/j.heliyon.2025.e41749.


Identifying Potential Autophagy Modulators in Panch Phoron Spices (P5S): An In Silico approach.

Parveen S, Ikhlas S, Faruqui T, Hasan A, Khatoon A, Saeed M ACS Omega. 2025; 10(1):871-884.

PMID: 39829452 PMC: 11740127. DOI: 10.1021/acsomega.4c07924.


Artificial Intelligence-Driven Computational Approaches in the Development of Anticancer Drugs.

Garg P, Singhal G, Kulkarni P, Horne D, Salgia R, Singhal S Cancers (Basel). 2024; 16(22).

PMID: 39594838 PMC: 11593155. DOI: 10.3390/cancers16223884.


In-silico study of novel dimeric flavonoid (OC251FR2) isolated from the seeds of Heckel () against alpha estrogen receptor (ER-α) of breast cancer.

Eugene-Osoikhia T, Odozi N, Yeye E, Isiaka M, Oladosu I In Silico Pharmacol. 2024; 12(2):108.

PMID: 39569035 PMC: 11573959. DOI: 10.1007/s40203-024-00282-5.


Cancer pharmacoinformatics: Databases and analytical tools.

Kamble P, Nagar P, Bhakhar K, Garg P, Sobhia M, Naidu S Funct Integr Genomics. 2024; 24(5):166.

PMID: 39294509 DOI: 10.1007/s10142-024-01445-5.


References
1.
Brimblecombe R, Duncan W, Durant G, Ganellin C, Parsons M, Black J . The pharmacology of cimetidine, a new histamine H2-receptor antagonist. Br J Pharmacol. 1975; 53(3):435P-436P. PMC: 1666433. View

2.
Henn R, Isenberg J, Maxwell V, Sturdevant R . Inhibition of gastric acid secretion by cimetidine in patients with duodenal ulcer. N Engl J Med. 1975; 293(8):371-5. DOI: 10.1056/NEJM197508212930802. View

3.
Chen Z, Li Y, Chen E, Hall D, Darke P, Culberson C . Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. J Biol Chem. 1994; 269(42):26344-8. View

4.
Ahmad T, Eisen T . Kinase inhibition with BAY 43-9006 in renal cell carcinoma. Clin Cancer Res. 2004; 10(18 Pt 2):6388S-92S. DOI: 10.1158/1078-0432.CCR-040028. View

5.
Shen C, Wang Y, Kovalevsky A, Harrison R, Weber I . Amprenavir complexes with HIV-1 protease and its drug-resistant mutants altering hydrophobic clusters. FEBS J. 2010; 277(18):3699-714. PMC: 2975871. DOI: 10.1111/j.1742-4658.2010.07771.x. View